Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
May 2020
-
Key ReleaseNovartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14Tabrecta (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14)…
-
It takes an R&D village to fight a pandemic
Gervais Tougas shares his experience working on a Novartis task force dedicated to fighting the COVID-19 pandemic.
-
Media ReleaseNovartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthmaCHMP positive opinion advances efforts to provide first-in-class LABA/LAMA/ICS combination for patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment in the EU. Digital…
April 2020
-
Featured NewsAI Nurse set to transform standards of care for heart failure patients in China
A new AI-enabled disease management tool in China aims to improve the lives of millions of patients with heart failure.
-
Media ReleaseNovartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrumCosentyx® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA)…
-
Featured NewsNovartis Financial Results – Q1 2020
Novartis announced the company’s financial results for the first quarter of 2020.
-
StatementNovartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
-
Key ReleaseNovartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19Au 1er trimestre 2020, chiffre d’affaires net des activités poursuivies1 en hausse de 13% (tcc2, +11% USD) avec une croissance à deux chiffres (tcc) d’Innovative Medicines et de Sandoz: Les…
-
Key ReleaseNovartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include Entresto USD 569…
-
Key ReleaseNovartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützenDer Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt im ersten Quartal 2020 um 13% (kWk2, +11% USD) mit zweistelligen Zuwächsen (kWk) bei Innovative Medicines und Sandoz: Zu den…
-
A visual tour of scientific strategies for combating coronavirus
Researchers around the world are collaborating to provide solutions to immediate and future challenges.
-
StatementNovartis announces flexible return to office and on-site field activities, starting May 11, 2020
Pagination
- ‹ Previous page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- …
- 150
- › Next page